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Increased mesangial cell hyaluronan expression
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The mechanism by which anti-DNA antibodies contribute to
the pathogenesis of lupus nephritis (LN) remains to be fully
elucidated. Hyaluronan (HA) is an important extracellular
matrix constituent that accumulates during tissue injury,
and participates in lymphocyte recruitment to sites of
inflammation. The role of HA in the pathogenesis of LN has
not been defined. We investigated the expression of HA in
renal biopsies and circulating HA levels in patients with
diffuse proliferative LN, and the effect of human anti-DNA
antibodies on HA synthesis in cultured human mesangial
cells (HMC). HA expression was increased in the mesangium,
and in the periglomerular and tubular distribution in LN
kidney biopsies. LN patients showed increased levels of
circulating HA, especially during active disease, which
correlated with anti-DNA antibody titers (r¼ 0.35,
P¼ 0.0234). Anti-DNA antibodies isolated during active LN
but not remission increased de novo synthesis of 3H-labeled
HA, which was accompanied by induction of HA synthase
(HAS) II transcription, and enhanced IL-1b, IL-6, and tumor
necrosis factor-a secretion in HMC (Po0.001 for all). Only
anti-DNA antibody induction of IL-1b enhanced HA synthesis,
which was abrogated by inhibitors of de novo mRNA or
protein synthesis. Our findings demonstrate that HA
expression is significantly increased within the mesangium
in diffuse proliferative LN mediated through anti-DNA
antibody-induced IL-1b. Given that HA plays a pivotal role
during inflammatory responses, influences cellular behavior
and assists in the recruitment of lymphocytes to sites of
injury, it is likely that HA contributes to the pathogenesis
of LN.
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Lupus nephritis (LN) is a common complication in systemic
lupus erythematosus (SLE), and an important cause of renal
failure. Anti-DNA antibodies represent a hallmark of SLE,
and are implicated in the pathogenesis.1–4 They can be eluted
from renal tissues in LN, and have been demonstrated to
bind to resident renal cells.2–4 The pathogenetic mechanisms
involving anti-DNA antibodies have not been fully eluci-
dated. An important step in the initiation and propagation of
inflammatory tissue damage is the recruitment of neutrophils
and mononuclear cells to sites of injury.5 In addition,
progression from acute to chronic inflammation is accom-
panied by increased synthesis and degradation of extra-
cellular matrix (ECM) components. Degradation of matrix
components generates fragments at sites of inflammation,
which may exhibit different biological activities from their
parent molecules.6,7 Hyaluronan (HA) is an important ECM
component that undergoes dynamic regulation during
inflammatory processes.8,9 HA is a non-sulfated glycos-
aminoglycan comprising repeating disaccharide units of
D-glucuronic acid and N-acetyl-D-glucosamine. In its native
form, HA occurs as a macromolecule of 1–6 106 Da.10 HA is
normally widely distributed within the ECM and on cell
surfaces, and is particularly enriched in pericellular matrices
surrounding migrating and proliferating cells during em-
bryonic development, tissue repair and tumorigenesis.11–13
Independent investigators have demonstrated increased
renal cortical HA expression in non-lupus crescentic
glomerulonephritis, allograft rejection and tubulo-interstitial
diseases.14–17 Studies in MRL/lpr mice have demonstrated
increased periglomerular and peritubular HA expression.18
Mesangial cells and the surrounding matrix are strategically
located juxtaposed to adjacent capillary loops, and they
interact with inflammatory mediators, immune deposits and
complement components. Mesangial cell proliferation,
mesangial deposition of anti-DNA antibodies and increased
expression of proinflammatory or profibrotic mediators are
prominent features in LN. The objective of this study was to
investigate the role of HA in the pathogenesis of LN. In vivo
studies were conducted to investigate circulating HA levels
and HA expression in renal biopsies in patients with LN.
Human polyclonal anti-DNA antibodies were isolated from
these patients serially during active disease and remission,
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and their effects on de novo HA synthesis in cultured human
mesangial cells (HMC) were investigated.
RESULTS
HA expression in renal biopsies and serum HA levels in
patients with LN
Healthy controls showed no glomerular HA expression
and minimal tubular HA staining (Figure 1d and g). LN
renal biopsies showed significant HA expression within the
mesangium, periglomerular area and tubules, and the inten-
sity of HA expression correlated with that of IgG deposition
in the glomerulus (Figure 1k–m). Three of the 12 biopsies
of active diffuse proliferative LN also showed increased HA
staining associated with glomerular lymphocytic infiltrates
(Figure 1f and i).
Circulating HA levels were elevated in patients with LN,
and serum HA levels were higher during active disease
compared with remission specimens (Figure 2a and Table 1).
Circulating HA levels correlated with the titer of anti-DNA
antibodies (Figure 2b).
Effect of anti-DNA antibodies on HA synthesis in HMC
The recovery of anti-DNA antibodies from serum samples
after affinity isolation was 75.174.1 and 76.376.0% for
remission and active samples, respectively, and IgG anti-DNA
antibodies accounted for 88.774.0 and 85.776.5% of serum
anti-DNA activity in remission and active samples, respec-
tively. Measurement of IgG1, IgG2, IgG3, and IgG4 levels in
anti-DNA antibody preparations showed that IgG1 was the
predominant isotype, and that the relative proportion of IgG4
was significantly higher during active disease compared with
samples obtained during remission (Table 2).
In accordance with our previous report, the results of
cellular enzyme-linked immunosorbent assay (ELISA) de-
monstrated that anti-DNA antibodies from patients with LN
showed significant binding to HMC compared with control
IgG (Figure 3a). Serum samples depleted of anti-DNA
antibodies (non-anti-DNA immunoglobulins) did not show
significant binding to HMC (Figure 3a).
HA synthesis in cultured HMC was not altered by non-
anti-DNA immunoglobulins, nor by Remission Ab samples
(anti-DNA antibodies isolated during remission), when
compared with normal human IgG (Figure 3b). In contrast,
anti-DNA antibodies isolated during active LN (Active Ab)
stimulated de novo synthesis of 3H-labeled HA in a time-
dependent manner, and HA was significantly increased in
both the conditioned medium (CM) and cell extract (CE)
fractions after 12 h of stimulation by Active Ab (Figure 4a).
At 24 h, Active Ab increased total 3H-labeled HA by 1.88-fold
compared with control IgG (Po0.001).
The hydrodynamic size of 3H-labeled HA synthesized
de novo was next investigated (Figure 4b and c). HA
synthesized by HMC in the presence of control IgG, similar
to that from cells exposed to medium alone (data not
shown), consisted of high molecular weight (HMW) HA that
eluted in the Vo of the column (P1). The
3H-labeled HA thus
synthesized accounted for 427.575.3 and 331.8731.7 dpm/
mg cellular protein in the CM and CE fractions, respectively,
and the distribution in the two compartments was 56% and
44% respectively. Remission Ab did not alter the hydro-
dynamic size or distribution of HA synthesized by HMC
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Figure 1 | Representative renal HA expression. Paraffin sections of
normal tissue obtained from patients who underwent nephrectomy
for tumor (a, d, g, and j) or renal biopsies from patients with diffuse
proliferative LN (b, c, e, f, h, i, k, and l) were subjected to staining
with eosin and hematoxylin (a–c). Sections were also used for
cytochemical staining for HA expression using the peroxidase–anti-
peroxidase method (d–i). Immunoreactive products were visualized
using diaminobenzidine as chromagen and counterstained with
hematoxylin. Constitutive HA expression was observed in the
periglomerular tissue and tubules but not within the glomerulus in
control specimens (d). Specimens obtained from LN patients
demonstrated increased HA expression in the glomerulus (asterisk),
in addition to increased periglomerular and tubular staining (e and f).
In 25% of LN biopsies, increased HA expression was also observed in
infiltrating cells in the glomerulus (f, arrow). Part of the glomerulus
(T) shown in d–f is magnified to facilitate comparison of HA
expression in control and LN renal tissues (g–i). Cryosections were
used to determine IgG deposition within the glomeruli (j–l). Original
magnification  200 (a–f) and (j–l). Original magnification  1600
(g–i). The expression of IgG deposition and HA in the glomerulus
were scored without knowledge of other clinical or laboratory
data (m).
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compared to control IgG (Figure 4b). In comparison,
64.675.6% of the HA synthesized in HMC upon stimulation
with Active Ab was secreted into the CM and 35.475.0%
was cell-associated. Active Ab not only increased HMW
HA in both fractions, but also induced the generation of
low molecular weight (LMW, P2) HA (904.0712.4 and
305.2724.1 dpm/mg cellular protein for P1 and P2, respec-
tively, in CM fraction and 645.7747.1 and 34.577.8 dpm/mg
cellular protein for P1 and P2, respectively, in CE fraction).
Mechanisms by which anti-DNA antibodies induced HA
synthesis in HMC
mRNA expression for the three HA synthase (HAS) isoforms
was investigated by reverse transcriptase-polymerase chain
reaction (RT-PCR). HAS II and III (but not HAS I) mRNAs
were constitutively expressed in the presence of serum-free
medium (data not shown), and were not altered by control
IgG (Figure 5). Anti-DNA antibodies induced HAS II
transcription, and the induction was more prominent with
Active Ab (Po0.05 and Po0.001 for Remission Ab and
Active Ab vs control IgG, respectively, and Po0.001 for
Remission Ab vs Active Ab). HAS III mRNA expression was
unaffected by anti-DNA antibodies.
The stimulatory effect of Active Ab on HA synthesis was
dependent on de novo mRNA and protein synthesis
(Figure 6), and induction of HA synthesis was abrogated
when the anti-DNA antibodies were pre-incubated with
exogenous DNA before their addition to HMC (Figure 4b
and c).
Previous studies have demonstrated that IL-1b, IL-6 and
tumor necrosis factor-a (TNF-a) can stimulate HA synthesis
in other cell types.19–21 As these cytokines are upregulated in
active LN,22 we investigated their potential role in modulat-
ing HA synthesis in HMC. Prior cytokine determination
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Figure 2 | Serum levels of HA in healthy controls and patients
with diffuse proliferative LN. (a) HA levels were measured in serum
samples obtained from control subjects and from patients with LN
during active disease and remission sequentially using a commercial
ELISA specific to HA (n¼ 20 for each group). Horizontal lines
represent the respective mean value of each group. Po0.001, active
LN vs LN in remission or controls. (b) Serum HA levels from active (K)
or inactive (J) LN patients correlated with the titers of anti-DNA
antibodies.
Table 1 | Comparison of total IgG concentration, anti-DNA antibody titer, HMC-binding IgG level, and HA concentration in
serum samples obtained from patients with LN obtained during active disease or remission
Remission Active LN P-value
(mean7s.d., n=20) (mean7s.d., n=20)
IgG concentration (mg/dl) 854.47214.1 1471.67524.3 0.001
Anti-DNA antibodies (IU/ml) 95.4754.2 305.8798.5 0.001
HMC-binding IgG (mg of HMC-bound IgG/mg cellular protein) 2.670.5 4.371.6 0.001
HA (ng/ml) 67.05756.98 225.407194.80 0.001
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Figure 3 | Comparison of HMC-binding activity between anti-DNA
antibodies and serum samples depleted of anti-DNA antibodies
(non-anti-DNA immunoglobulins) obtained from lupus patients
during inactive and active disease (a). Horizontal line represents
the mean value of each group. *Po0.001, Active Ab or inactive Ab vs
control IgG. De novo synthesis of 3H-labeled HA by HMC after
incubation with control IgG, non-anti-DNA immunoglobulins (non-
anti-DNA Ig) or anti-DNA antibodies (10 mg/ml IgG final concentration
for all) for 24 h (b). Samples of CM were dialyzed into 8 M urea buffer,
pH 6.0, and loaded onto DEAE-Sephacel columns to remove
contaminating proteins and glycoproteins. Samples were further
purified by Uno Q anion-exchange chromatography and samples
eluting with 0.45 M NaCl were collected, digested with papain and
subjected to gel filtration chromatography on Sepharose CL-4B under
dissociative conditions to separate 3H-labeled HA from digested
material. 3H-labeled HA eluted in the void volume of the column and
fractions with radioactivity were pooled, and an aliquot subjected to
beta scintillation counting to determine total 3H-labeled HA
synthesized under control and experiment conditions. Horizontal
lines represent the respective mean values for de novo synthesis of
3H-labeled HA in each group.
Table 2 | Relative proportions of different IgG isotypes in
anti-DNA antibody preparations
IgG
isotype
Percentage of total
IgG during remission
Percentage of total
IgG during active disease P-value
IgG1 60.2778.95 52.3378.45 0.101
IgG2 26.30712.26 35.4879.53 0.137
IgG3 11.1676.07 7.5573.31 0.366
IgG4 2.2571.74 4.6572.20 0.035
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showed no cytokine activity to IL-1b, IL-6, and TNF-a in all
anti-DNA antibody preparations (data not shown). Remis-
sion Ab did not induce these cytokines in HMC (Figure 7).
Active Ab induced the secretion of IL-1b, IL-6, and TNF-a in
HMC by 2.20 , 2.28 , and 1.75 , respectively (26.876.4,
24.177.4, and 17.276.0 pg/mg cellular protein for IL-1b, IL-6,
and TNF-a, respectively; Po0.001 for all when compared
to control IgG or Remission Ab). Neutralizing antibodies to
IL-6 or TNF-a had no effect on the induction of HA synthesis
by Active Ab (Figure 8a). In contrast, the stimulatory effect
of Active Ab on total HA synthesis was abrogated by IL-1
receptor antagonist in a dose-dependent manner (Figure 8a).
Maximum inhibition was observed with 1 mg/ml IL-1
receptor antagonist, which abrogated both HMW and
LMW 3H-labeled HA synthesis (Figure 8b).
DISCUSSION
Severe proliferative LN remains an important cause of
acute or chronic renal failure. Although the deposition of
anti-DNA antibodies and inflammatory mediators within
the kidney parenchyma are well demonstrated in LN, the
pathogenetic mechanisms pertaining to inflammatory and
fibrotic processes have not been fully elucidated. There is
accumulating evidence that HA is involved in immune-
mediated renal injury.15,23–28 Expression of HA in normal
kidneys is limited to the medullary and papillary interstitium,
where it helps to maintain the oncotic pressure for urinary
concentration.23,24 Increased renal HA expression occurs
in animal models of autoimmune crescentic glomerulo-
nephritis, renal ischemia and kidney allograft rejection, and
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Figure 4 | Total 3H-labeled HA synthesized by HMC in relation to the duration of incubation with control IgG (&), Remission Ab ( ) or
Active Ab (’) in the presence of [3H]-glucosamine for periods up to 24 h (a). At select time points, the CM was decanted and the cells
extracted with 4 M GuHCl/4% CHAPS. 3H-labeled HA was purified by a combination of dialysis and anion-exchange chromatography. The results
are mean7s.d. of three separate experiments. *Po0.05 compared to control IgG. Gel filtration chromatography of 3H-labeled HA synthesized
de novo in HMC. Equal aliquots (100 ml) of (b) CM or (c) CE obtained from cells stimulated with control IgG (J), Remission Ab ( ) or Active Ab (K)
were subjected to gel filtration chromatography under dissociative condition. The increase in 3H-labeled HA synthesis upon stimulation with
Active Ab (upper panels) was abrogated when anti-DNA antibodies were preincubated with exogenous DNA (5 mg/ml) before addition to HMC
(bottom panel). P1 and P2 represent HMW and LMW 3H-labeled HA respectively. Vo and Vt represent the void and total volume of the column,
respectively.
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Figure 5 | RT-PCR for HAS II and HAS III mRNA after stimulation
with anti-DNA antibodies or control IgG. Total RNA was extracted
from HMC using TriReagent according to the manufacturer’s
instructions and 1 mg of total RNA reverse transcribed to cDNA before
PCR amplification for HAS I, II, and III transcripts. (a) PCR products
were separated by flat bed electrophoresis on a 2% agarose gel. HAS
I was not expressed by HMC. a-Actin was used as the housekeeping
gene. (b) Primer to a-actin mRNA densitometric ratios are shown for
control IgG (&), Remission Ab ( ) and Active Ab (’). *Po0.05,
control vs Remission Ab; **Po0.001, Active Ab vs control IgG or
Remission Ab.
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Figure 6 | Effect of actinomycin D or cycloheximide on the
induction of 3H-labeled HA synthesis in HMC by anti-DNA
antibodies. Confluent growth-arrested HMC were incubated in the
absence (’) or presence of actinomycin D (5 mg/ml, ) or
cycloheximide (5 mg/ml, &) for 1 h before stimulation of cells with
control IgG or anti-DNA antibodies for another 24 h. The results show
that HA induction by anti-DNA antibodies is dependent on de novo
gene transcription and translation. Data represent mean values and
s.d. of three individual experiments. *Po0.01, with or without drug
treatment, or compared with control IgG.
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increased renal cortical HA expression has been observed
in various human acute or chronic inflammatory renal
diseases.16,25–28 Feusi et al.18 demonstrated the expression of
HA in the tubulo-interstitium and crescents of mice with LN,
but not within the mesangium. Our findings from renal
tissue of patients with diffuse proliferative LN show increased
HA expression in a periglomerular, mesangial, and tubulo-
interstitial distribution. The discrepancy with regard to
mesangial HA expression could be related to differences
between species or staining procedures. HA normally binds
to various matrix molecules such as aggrecan, versican or
CD44,29 and such binding may interfere with the binding by
exogenous HA-binding protein, thereby leading to false-
negative staining. In this respect, all samples in the present
study were treated with papain to remove proteins bound to
HA in order to prevent false-negative staining results.
Approximately 65% of the HA synthesized by HMC in
the presence of Active Ab was secreted into the CM. This
could explain the prominent periglomerular (in addition to
intraglomerular) HA expression in LN renal tissues. As HA
can bind or induce chemokine/cytokine synthesis and
upregulate the expression of adhesion molecules, HA
assumes a pivotal role in the recruitment and retention of
lymphocytes at sites of inflammatory tissue injury.8,30–32
Lymphocytes can thus bind, via abundant CD44 on their
cell surface, to secreted HA molecules or HA molecules
still associated with mesangial cells. Other investigators have
also shown that HA can modulate monocyte infiltration
and transmigration through their binding to CD44.33 In this
regard, 25% of LN renal biopsy samples showed significant
HA staining on infiltrating cells within the glomerulus. The
association between mesangial HA expression and IgG depo-
sition also suggests the possibility that anti-DNA antibodies
might influence the synthesis of HA in HMC. The correlation
between the increased circulating HA levels and anti-DNA
antibody titers in patients with LN lends support to the
hypothesis that anti-DNA antibodies might be involved in
the induction of HA.
HA subpopulations of different molecular weights can
exert different effects on T-lymphocyte-mediated liver injury
in mice.34 Chemical insult such as hyperglycemia can
also stimulate HA synthesis in rat mesangial cells and lead
to increased monocyte adhesion.35 Anti-DNA antibodies
have been demonstrated to crossreact with proteoglycans
and HA.36,37 Given that HA can also bind to complement,38
the interaction between anti-DNA antibodies, complement
components, resident or infiltrating cells in the renal paren-
chyma could occur via HA and result in the propagation of
local inflammatory processes.
Data from the in vitro studies show that anti-DNA
immunoglobulins obtained from patients during active LN
could induce de novo HA synthesis in HMC. Polymerization
of HA occurs at the plasma membrane through the action of
one or more of three HA synthase isomers.39 These enzymes
orchestrate the polymerization and translocation of HA
out of the cell into the pericellular or ECM, and the three
isoforms have distinct tissue and temporal expressions
that dictate their respective roles in the regulation of HA
biosynthesis.39 Previous studies have shown that only HAS II
is essential for tissue development, whereas the roles of
HAS I and III have not been fully elucidated. In this study, we
have shown that HMC constitutively expressed HAS II and
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Figure 7 | Effect of anti-DNA antibodies on IL-1b, IL-6, and TNF-a secretion in HMC. Confluent growth-arrested HMC were stimulated with
control IgG or anti-DNA antibodies for 24 h. The culture medium was decanted, centrifuged to remove cell debris and the levels of (a) IL-1b,
(b) IL-6, and (c) TNF-a determined using commercial ELISAs. Horizontal bars represent the mean value of each group. Po0.001, compared with
control IgG or Remission Ab.
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Figure 8 | (a) Effect of neutralizing antibodies to IL-6 and TNF-a,
and IL-1 receptor antagonist on de novo 3H-labeled HA synthesis.
HMC were incubated with varying concentrations of neutralizing
antibodies to IL-6 and TNF-a, and IL-1 receptor antagonist (0–25 mg/
ml) for 1 h before the addition of Active Ab for a further 24 h. The CM
was assessed for 3H-labeled HA. *Po0.01, compared to samples not
incubated with IL-1 receptor antagonist. (b) Gel filtration chromato-
graphy of 3H-labeled HA synthesis. To determine the modulatory
effect of IL-1 receptor antagonist on 3H-labeled HA synthesis by
Active Ab, HMC were incubated with control IgG in the presence (&)
or absence (’) of IL-1 receptor antagonist (1 mg/ml), or Active Ab in
the presence (J) or absence (K) of IL-1 receptor antagonist. Aliquots
of CM (upper panel) and CE (lower panel) were chromatographed on
Sephacryl S-1000 under dissociative conditions. Vo and Vt represent
the void and total volume of the column, respectively.
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III but not HAS I mRNA. Anti-DNA antibodies obtained
from active LN stimulated de novo HA synthesis in HMC
through induction of HAS II gene expression. Although HAS
II mRNA was also induced by anti-DNA antibodies during
remission, this appears insufficient to result in significant
de novo HA synthesis. As identical concentrations of anti-
DNA antibodies were used in these experiments, the data
highlight the functional heterogeneity of anti-DNA anti-
bodies at different phases of disease, and imply that anti-
DNA antibodies still detectable during clinical remission
might be ‘less pathogenic’. The results on IgG isotypes
confirmed the predominance of IgG1 in anti-DNA antibody
preparations.40,41 Some investigators have suggested an asso-
ciation between IgG1 and IgG3 anti-DNA antibodies with
renal disease, whereas others have observed an association
between IgG2 anti-DNA antibodies and nephritic flare.
40,41 It
is of interest to note the increase in the relative abundance of
IgG4 isotype during active disease. This isotype association
with disease activity requires confirmation with more clinical
samples, and the pathogenetic implications remain to be
investigated.
Multiple proinflammatory cytokines are induced during
active LN.22 Our results show that IL-1b, IL-6, and TNF-a
were induced in HMC by ‘Active’ but not ‘Remission’ anti-
DNA antibodies, and that IL-1b is involved, at least in
part, in the induction of de novo HA synthesis in HMC by
anti-DNA antibodies.
HA has been implicated in the amplification of inflam-
matory and/or remodeling processes in kidney tissues.28,42 In
general, HMW HA is primarily involved in normal
physiologic processes whereas the generation of LMW HA
occurs under pathological circumstances. Independent re-
searchers have demonstrated that an ECM enriched with
HMW HA favors smooth muscle cell proliferation but
inhibits vascular endothelial cell proliferation and migra-
tion.43–45 HMW HA can also form intercellular cables that act
as an inflammatory matrix for the retention of leukocytes at
sites of injury. Intermediate-size HA (Mr 0.2 106 Da) can
induce multiple chemokines in alveolar macrophages,8 and
HA oligosaccharides have been demonstrated to induce
collagen type I and III in rat lung fibroblasts.46 Although it
has been suggested that the accumulation of HA molecules in
injured tissues could lead to an excessive fibrotic response,46
recent studies have shown that HMW HA (2 106 Da) could
antagonize the induction of collagen types III and IV by
TGF-b1 in human proximal tubular epithelial cells, thereby
limiting progressive fibrosis and facilitating reparative
processes following injury.47 Our results show that both
LMW and HMW HA molecules are induced in HMC by
anti-DNA antibodies during active LN. We speculate that
these HA molecules are involved in distinct proinflammatory
or reparative processes, the balance of which could influence
fibrotic and healing processes following an episode of
acute LN.
In conclusion, we have demonstrated that during the
acute phase of diffuse proliferative LN patients have high
circulating levels of HA, which correlate with anti-DNA
antibody titers, and that anti-DNA antibodies could
stimulate the synthesis of both HMW and LMW HA in
mesangial cells through the induction of HAS II and IL-1b.
The HA thus synthesized could play a significant patho-
genetic role in inflammatory, fibrotic and healing processes,
by virtue of their interaction with cytokines, adhesion mole-
cules and mononuclear inflammatory cells.
MATERIALS AND METHODS
Serum samples from patients with LN
Sequential serum samples that demonstrated high IgG binding to
HMC were collected from 20 patients with biopsy-proven diffuse
proliferative LN (15 women and five men, mean age 42.577.5 and
43.778.9 years, respectively). Each patient contributed two samples,
one during active disease and another during remission (defined by
clinical manifestations together with SLE Disease Activity Indices
(SLEDAI) ofX10 ando4, respectively).48 Immune complexes were
removed by polyethylene glycol precipitation.2 Sera from 20 sex- and
aged-matched healthy individuals were used as controls.
Studies on renal biopsies
A total of 12 renal biopsies showing active diffuse proliferative LN
(Class IV) were included. Normal kidney tissue from five patients
who underwent nephrectomy for tumor was included as control.
Unless otherwise stated, all incubations were for 1 h at 371C. Paraffin
sections were stained with eosin and hematoxylin (Sigma, Tin Hang
Technology Ltd, Hong Kong) according to standard procedures. To
detect HA expression, paraffin sections were digested with papain
(15 IU/ml) in 200 mM sodium acetate, pH 6.0, for 1 h at 601C before
incubation with biotinylated HA binding protein (1:50) overnight
at room temperature.49 Samples were then washed in phosphate-
buffered saline (PBS) and incubated with streptavidin-conjugated
horseradish peroxidase secondary antibody. Signal detection was
by the peroxidase–anti-peroxidase method (Dako, Gene Company,
Hong Kong) with hematoxylin counterstaining. Glomerular staining
was graded as previously described (0: no staining; 1þ : faint
staining; 2þ : moderate staining; 3þ : intense staining).50 To detect
IgG deposition, cryosections were incubated with fluorescein
isothiocyanate-conjugated goat anti-human IgG (dilution 1:100).
After washing with PBS, sections were mounted with fluorescence
mountant (DAKO, Gene Company, Hong Kong) and epifluores-
cence was viewed using an Axiovert 135 inverted microscope (Zeiss,
Gold Pacific Ltd, Hong Kong). All samples were coded and
evaluated without the knowledge of the clinical information. Four
separate fields of each specimen were taken. The extent and intensity
of staining was scored semiquantitatively (0: absent; 1þ : mild; 2þ :
moderate; 3þ : marked; 4þ ; severe), and a mean score was calcu-
lated for each sample.50
In vitro studies on HMC
Primary cultures of HMC were established from nephrectomized
kidneys and maintained in RPMI 1640 medium supplemented with
15% fetal bovine serum (FBS).2 All experiments were performed on
cells of the 5–7th passages that had been growth-arrested for 72 h, in
the absence of serum and complement components. Cells were
stimulated with either human IgG anti-DNA antibodies or normal
human IgG at a final concentration of 10 mg/ml for periods up to
24 h. This dose was chosen as preliminary studies demonstrated a
dose-dependent response of IgG binding to HMC up to 10 mg/ml.
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Addition of higher concentrations of IgG did not result in further
IgG binding to HMC. To determine whether the effect of anti-DNA
antibodies on HA synthesis in HMC was dependent on de novo
mRNA or protein synthesis of HAS I, II, and III, parallel experi-
ments were performed in the presence of actinomycin-D (5mg/ml)
or cycloheximide (5mg/ml), respectively. Preliminary experiments
showed maximum inhibition of gene transcription and mRNA
translation at these doses, without significant cytotoxic effect. To
investigate the mechanisms by which anti-DNA antibodies modu-
lated HA synthesis in HMC, cells were incubated with neutralizing
antibodies to IL-6 or TNF-a, or with IL-1 receptor antagonist for 1 h
before incubation with anti-DNA antibodies.
Measurement of total IgG or IgG isotypes in serum samples
or anti-DNA antibody preparations
IgG concentration in serum samples or anti-DNA antibody
preparations was measured by ELISA as described previously.2
The concentrations of IgG1, IgG2, IgG3, and IgG4 in anti-DNA
antibody preparations were determined using a commercial human
IgG subclass profile ELISA kit according to the manufacturer’s
instructions (Zymed Laboratories, Onwon Trading Limited, Hong
Kong). The detection ranges were 0.43–13.72, 0.17–5.32 , 0.042–1.34,
and 0.024–0.76 mg/ml, respectively, for IgG1, IgG2, IgG3, and IgG4.
Cellular ELISA to determine immunoglobulin binding to HMC
HMC were seeded into 96-well tissue culture plates at a density of
10 000 cells/cm2 in RPMI 1640 containing 15% FBS until 90%
confluent. The cells were then depleted of serum for 72 h before
determining the amount of IgG bound to HMC.2 In some
experiments, anti-DNA antibodies were premixed with DNA at
concentrations of 0–10mg/ml for 2 h at 371C before incubation with
HMC to investigate the specificity of the anti-DNA antibodies. The
amount of IgG bound to HMC was expressed as mg HMC-bound
IgG/mg cellular protein and seropositivity for HMC binding was
defined by readings exceeding meanþ 3s.d. of control.2 To
determine total cellular protein, HMC cultured in 96-well plates
were lysed with 4 M urea buffer, 20 mM sodium acetate, pH 6.0,
containing 1% Triton X-100 (50 ml). Protein content was then
measured using a modified Lowry assay (BioRad, Hong Kong).
Isolation of human polyclonal anti-DNA antibodies from
patients with LN
Polyclonal IgG anti-double-stranded DNA antibodies were isolated
from sera of LN patients using sequential affinity chromatography,
and the IgG level was determined, as previously described.2 Their
purity was confirmed by 10% SDS-PAGE and ability to bind
exogenous DNA. Anti-DNA activity in serum samples and anti-
DNA antibody preparations was determined using a commercial
ELISA (Microplate autoimmune anti-DNA quantitative ELISA,
BioRad, Hong Kong). The detection range was 20–1000 IU/ml,
and readings of 460 IU/ml indicated positive results.
HAS I, II, and III mRNA expression by RT-PCR
HMC RNA was extracted with TriReagent (Onwon Trading Limited,
Hong Kong) according to the manufacturer’s instructions. A 1 mg
portion of total RNA was reverse transcribed to cDNA with M-MLV
reverse transcriptase using the random hexamers method and
amplified using PCR in a total volume of 20 ml, as previously
described.49,51 After amplification, 10 ml of both test and control
PCR reaction mix was separated by electrophoresis on a flat-bed
agarose gel (2% w/v). Images of the gels were captured using the
ChemiGenius gel documentation system, and the density of bands
determined with the ChemiGenius analysis software (Syngene, Gene
Company, Hong Kong). Results were expressed as the ratio of HAS
I, II, and III to a-actin expression. The primer sequences used are as
follows:
Measurement of cytokine concentration in culture
supernatant
HMC were incubated with anti-DNA antibodies or control IgG for
24 h. The supernatant was decanted, centrifuged at 2000 g for 10 min
to remove cell debris and the levels of IL-1b, IL-6, and TNF-a were
measured using respective commercial ELISA kits according to the
manufacturer’s instructions (PharMingen, Bio-Gene, Hong Kong).
The detection ranges were 5–300 pg/ml for IL-6 and IL-1b, and
15–1000 pg/ml for TNF-a.
Measurement of HA in serum samples
HA levels were determined in serum samples obtained from control
subjects or patients with diffuse proliferative LN using a commercial
HA ELISA according to the manufacturer’s instructions (Corgenix,
Denver, CO, USA). Detection range for HA was 10–1000 ng/ml
and the ELISA showed no crossreactivity to other glycosamino-
glycans.
Measurement of de novo HA synthesis by metabolic labeling
and extraction of 3H-labeled HA
Confluent growth-arrested HMC were radiolabeled with D-6-3H-
glucosamine hydrochloride (25 mCi/ml; Amersham Biosciences,
Hong Kong) for 24 h as previously described,19,52 and the CM
decanted. Cell-associated 3H-labeled macromolecules were extracted
with 4 M guanidine-HCl and 4% CHAPS.19 Samples were buffered,
exchanged into 8 M urea, 20 mM Bis-Tris, pH 6.0, containing 0.1%
CHAPS and applied to DEAE-Sephacel columns equilibrated in the
same buffer. Unbound material was washed with 8 M urea buffer
containing 0.15 M NaCl to remove 3H-labeled glycoproteins. 3H-
labeled HA was eluted with the above buffer containing 0.3 M NaCl,
dialyzed into 8 M urea buffer containing 0.15 M NaCl and further
purified on a Uno Q column equilibrated in the same buffer,
interfaced with a Biologic Workstation (BioRad, Hong Kong).
3H-labeled HA was washed with (a) 0.1 M NaCl (10 ml) and (b) 0.3 M
NaCl (10 ml) before elution with a linear NaCl gradient (15 ml). In
all, 0.5 ml fractions were collected and monitored for radioactivity
by scintillation beta counting. Total eluted 3H-labeled HA was
further concentrated by ethanolic potassium acetate precipitation in
the presence of carrier HA (50 mg/ml), washed with 95% ethanol,
dried under nitrogen and stored at 201C until analysis of its
Primer Sequence bp
HAS I forward 50-AGCAGGACGCGCCCAAGCCCACTC-30 562
HAS I reverse 50-TCCTCCGCCTCCACCTCCCGATAG-30
HAS II forward 50-TCCCGGTGAGACAGATGAGT-30 495
HAS II reverse 50-ACCCGGTTCGTGAGATGC-30
HAS III forward 50-AGTGCAGCTTCGGGGATGA-30 453
HAS III reverse 50-TGATGGTAGCAATGGCAAAGAT-30
a-Actin forward 50-GGAGCAATGATCTTGATCTT-30 204
a-Actin reverse 50-TCCTGAGGTACGGGTCCTTCC-30
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hydrodynamic size by Sephacryl S-1000 gel filtration chromato-
graphy under dissociative conditions.19,52
Qualitative assessment of HA by gel filtration
chromatography
To determine the hydrodynamic size of 3H-labeled HA, equal
volumes of the CM and CE from HMC cultured under control or
experimental conditions were treated with papain (15 IU/ml, 100 ml)
at 601C for 1 h. Following papain inactivation with 4 M guanidine
HCl buffer (400 ml), the material was chromatographed on an
analytical Sephacryl S-1000 column (0.05 1.2 m). To confirm the
presence of 3H-labeled HA, aliquots of papain-treated samples were
further incubated with Streptomyces hyaluronidase (50 mIU/ml)
before gel filtration chromatography.19,52 Fractions (0.5 ml) were
collected at a rate of 2.4 ml/h, and the radioactivity was monitored
by scintillation beta counting. The void (Vo) and total (Vt) volume
of each column were calibrated with purified 3H-labeled HA from
HMC cultured with 15% FBS and unincorporated [3H]-glucosa-
mine, respectively. The hydrodynamic size of 3H-labeled HA
synthesized de novo was calculated using the equation [(Ve–Vo)/
(Vt–Vo)], where Ve represents the fraction number of the eluted
sample/peak.
Statistics
All experiments were repeated three times. Results are expressed
as mean7s.d. Statistical analysis was performed using GraphPad
Prism version 3.00 for Windows (GraphPad Software, San Diego,
CA, USA). Results with ‘Active Ab’, ‘Remission Ab’ and controls were
compared using the Mann–Whitney U-test. Correlations bet-
ween IgG deposition and HA expression in renal biopsies, and
between serum HA and anti-DNA levels were examined using the
Spearman’s method. Two-tailed Po0.05 was considered statistically
significant.
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